Contoura vs Wavefront Optimized Ablation

Sponsor
Hebatallah MT Abdelmoniem (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05829980
Collaborator
(none)
128
22

Study Details

Study Description

Brief Summary

To evaluate the efficacy, safety and accuracy of Contoura topography-guided LASIK & PRK in comparison to Wavefront optimized LASIK & PRK in virgin eyes with astigmatism.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Laser assisted in-situ keratomileusis
  • Procedure: Photorefractive keratectomy

Detailed Description

In Upper Egypt, The second principal cause of blindness was uncorrected refractive errors accounting for 16% of sample population. It was reported that astigmatism (defined as cylinder power > 0.5 D) was the most common refractive errors in children and adults followed by hyperopia and myopia.

Laser vision correction has been established over the last 2 decades as a safe and effective intervention to treat refractive errors, being one of the main techniques practiced globally.

However, many subjects after LASIK had uncorrected distance visual acuity (UDVA) greater than 1.0, they complain about poor night vision, glare, and double vision. As studies have shown that every 1° deviation of the astigmatic axis could result in loss of correction of 3.3%. Even residual astigmatism less than 0.50D could have an actual impact on visual quality.

Excimer laser ablation used in the correction of refracted errors especially astigmatism may reduce quality of vision, and that is attributed to the induced optical aberrations. The most prevalent of these optical aberrations is the spherical aberration.

Among multiple sophisticated profiles that developed to optimize visual outcomes, wavefront optimized profile which compensate for corneal curvature to reduce spherical aberration.

The topographic guided profiles which consider the shape of the anterior corneal surface. Contoura topography guided ablation corrects astigmatic power and axis to create a more uniform, aberration-free cornea.

Treating astigmatism can be challenging as the conventional patterns of Excimer laser treatment of astigmatism is known to be less predictable than that of spherical refractive errors.

Study Design

Study Type:
Observational
Anticipated Enrollment :
128 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Contoura Topography-guided Ablation Versus Wavefront-optimized Ablation for Correction of Astigmatism
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Apr 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Group A

Contoura topography-guided LASIK

Procedure: Laser assisted in-situ keratomileusis
Laser-Assisted In Situ Keratomileusis is a procedure that permanently changes the shape of the cornea using an excimer laser and the mechanical microkeratome (a blade device) used to cut a flap in the cornea.
Other Names:
  • LASIK
  • Group B

    Contoura topography-guided PRK

    Procedure: Photorefractive keratectomy
    Photorefractive keratectomy is a laser refractive procedure used to ablate the corneal stroma to correct refractive errors without cutting flap
    Other Names:
  • PRK
  • Group C

    Wavefront-optimized LASIK

    Procedure: Laser assisted in-situ keratomileusis
    Laser-Assisted In Situ Keratomileusis is a procedure that permanently changes the shape of the cornea using an excimer laser and the mechanical microkeratome (a blade device) used to cut a flap in the cornea.
    Other Names:
  • LASIK
  • Group D

    Wavefront-optimized PRK

    Procedure: Photorefractive keratectomy
    Photorefractive keratectomy is a laser refractive procedure used to ablate the corneal stroma to correct refractive errors without cutting flap
    Other Names:
  • PRK
  • Outcome Measures

    Primary Outcome Measures

    1. Change in Postoperative UDVA compared to preoperative CDVA (in LogMAR) [3 month]

      UCVA 3 month after surgery compared to baseline preoperative CDVA

    2. Number of lines of preoperative CDVA compared to postoperative [3 month]

      Change in lines of CDVA from baseline preoperative to 3 month postoperative (in LogMAR)

    3. Amount of Residual Astigmatism postoperatively (in Diopters) [3 month]

      residual astigmatism 3 month postoperatively

    4. Postoperative mean spherical equivalent MSE compared to Preoperative MSE (in Diopters) [3 month]

      changes in mean spherical equivalent baseline preoperative to 3 month postoperative

    Secondary Outcome Measures

    1. Change in Contrast sensitivity test [3 month]

    2. Amount of High order aberrations [3 month]

      (Spherical aberration, trefoil, vertical & horizontal coma)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • Astigmatism (up to 5.0 diopters) or less.

    • Central corneal thickness (CCT) of 500 microns or more

    • Estimated Residual stromal bed thickness (RSB) of 280 microns or more

    • Subject has provided written informed consent

    Exclusion Criteria:
    • Keratoconus

    • Abnormal topography

    • previous ocular trauma or eye surgery

    • pre-existing diseases of the vitreous, macula, or optic nerve that can affect visual outcome

    • patients with uveitis and anterior segment pathology

    • patients with corneal pathology or Severe dry eye

    • pregnancy or breast-feeding females

    • uncontrolled vascular or autoimmune disease

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Hebatallah MT Abdelmoniem

    Investigators

    • Study Chair: Mohamed A. Sayed, Ass. Prof., Assiut University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Hebatallah MT Abdelmoniem, Assistant Lecturer, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05829980
    Other Study ID Numbers:
    • CONvsWFO
    First Posted:
    Apr 26, 2023
    Last Update Posted:
    Apr 26, 2023
    Last Verified:
    Apr 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hebatallah MT Abdelmoniem, Assistant Lecturer, Assiut University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 26, 2023